Catherine Cifuentes-Rojas Releases Go/No-Go Checklist for Biotherapeutic Discovery Teams

Catherine Cifuentes-Rojas, a director at Ginkgo Bioworks, has released a publicly available checklist designed to assist biotherapeutic discovery teams in evaluating early-stage programs. The framework provides five standardized questions meant to be addressed before moving a project to subsequent investment stages. By implementing this documentation process, teams can systematically review data and potential disconfirming evidence, aiming to standardize decision-making protocols across various scientific disciplines without relying on proprietary software or internal corporate hierarchies during the research and development lifecycle.

The introduction of a standardized evaluation checklist addresses a recurring challenge in biopharmaceutical development: the tendency for momentum to override critical data analysis during the early stages of drug discovery. By requiring teams to formally document answers to specific questions regarding assay replication, hypothesis testing, and in vivo performance, the framework institutionalizes the process of identifying potential failure points. This approach aims to replace subjective decision-making driven by seniority with evidence-based documentation, potentially reducing the duration and cost of unproductive research programs that might otherwise continue due to internal bias or lack of structured dissent.

From an industry perspective, this resource highlights the growing emphasis on cross-functional alignment within large-scale biotechnology operations. As teams become increasingly multidisciplinary, incorporating expertise from computational science, biology, and engineering, the need for a common decision-making language becomes essential. By providing a non-proprietary tool, the framework offers organizations of various sizes a method to bridge communication gaps between different technical departments. If widely adopted, such structured protocols may influence how discovery teams allocate resources, emphasizing the early identification of programs that fail to meet objective criteria. This shift toward systematic, documented evaluation reflects a broader trend in the life sciences sector toward increasing transparency and rigor in the pre-clinical development process, ensuring that capital is preserved for projects that demonstrate robust experimental support and clearly defined success metrics.